Parameter
| Biomarker | BCL-2 | Full name | B-cell lymphoma 2 | Molecular Type | Protein (Apoptosis regulatory protein) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Therapeutic targets, prognostic evaluation |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Blood and lymphoid tissue | Test Sample / Technology Platform | Tumor tissue (immunohistochemistry, Western blot) | ||
| Pathobiological Mechanisms | Regulates apoptosis, is highly expressed in cHL, and is associated with tumor cell survival. Venetoclax can induce apoptosis in its positive cells. | ||||
| Clinical Availability Status | Research/Drug Development Phase: Venetoclax exhibits cytotoxicity against cHL cell lines, providing a basis for novel targeted therapy. | ||||
| Notes and Dynamics | Research/Drug Development Phase: Venetoclax exhibits cytotoxicity against cHL cell lines, providing a basis for novel targeted therapy. | ||||